PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω‐Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Fatty liver disease is a common lipid metabolism disorder influenced by the combination of individual genetic makeup, drug exposure, and life‐style choices that are frequently associated with metabolic syndrome, which encompasses obesity, dyslipidemia, hypertension, hypertriglyceridemia, and insulin resistant diabetes. Common to obesity related dyslipidemia is the excessive storage of hepatic fatty acids (steatosis), due to a decrease in mitochondria β‐oxidation with an increase in both peroxisomal β‐oxidation, and microsomal ω‐oxidation of fatty acids through peroxisome proliferator activated receptors (PPARs). How steatosis increases PPAR α activated gene expression of fatty acid transport proteins, peroxisomal and mitochondrial fatty acid β‐oxidation and ω‐oxidation of fatty acids genes regardless of whether dietary fatty acids are polyunsaturated (PUFA), monounsaturated (MUFA), or saturated (SFA) may be determined by the interplay of PPARs and HNF4 α with the fatty acid transport proteins L‐FABP and ACBP. In hepatic steatosis and steatohepatitis, the ω‐oxidation cytochrome P450 CYP4A gene expression is increased even with reduced hepatic levels of PPAR α. Although numerous studies have suggested the role ethanol‐inducible CYP2E1 in contributing to increased oxidative stress,Cyp2e1‐null mice still develop steatohepatitis with a dramatic increase in CYP4A gene expression. This strongly implies that CYP4A fatty acid ω‐hydroxylase P450s may play an important role in the development of steatohepatitis. In this review and tutorial, we briefly describe how fatty acids are partitioned by fatty acid transport proteins to either anabolic or catabolic pathways regulated by PPARs, and we explore how medium‐chain fatty acid (MCFA)CYP4A and long‐chain fatty acid (LCFA)CYP4Fω‐hydroxylase genes are regulated in fatty liver. We finally propose a hypothesis that increased CYP4A expression with a decrease in CYP4F genes may promote the progression of steatosis to steatohepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 2×
“[20] J.”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“In patients with NAFLD, 59% of TAG fatty acid is derived from adipose lipolysis while 26% is from DNL and 15% from the dietary NEFA pool [21].”
BackgroundLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“progress to hepatocellular carcinoma [59, 60].”
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 2×
“It is presently unknown why hyperinsulinemia activates the lipogenic pathway, but fails to prevent the inactivation of a gluconeogenic pathway and hyperglycemia observed in insulin resistant diabetes [127, 129, 130].”
BackgroundInoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577 · cited 2×
“Consequently, LCFA activation of HNF4α with ACBP would increase plasma levels of lipid rich lipoproteins (VLDL, LDL, and HDL) and their constituent apolipoproteins (AI, AII, B, and CIII).”
BackgroundThe Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
Biochemistry of mammalian peroxisomes revisited
Wanders, R. J. A., & Waterham, H. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133329 · Cited by 995 · cited 2×
“[133] R.”
BackgroundPeroxisomes and oxidative stress
Schrader, M., & Fahimi, H. D. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.09.006 · Cited by 838
(2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823098 · Cited by 481
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476 · cited 8×
“It is difficult to reconcile the effect of the PPARα agonist in the prevention of steatohepatitis in Pparα-null mice since none of the mitochondrial, peroxisomal β-oxidation, and microsomalω-oxidation pathways was induced by Wy14,643 in these mice.”
BackgroundInfluential
Cited by
Begriche, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., & Fromenty, B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.006 · Cited by 555
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Souza-Mello, V. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i8.1012 · Cited by 182
Kim, D.-H., Kim, H., Jeong, D., Kang, I.-B., Chon, J.-W., Kim, H.-S., Song, K.-Y., & Seo, K.-H. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.02.014 · Cited by 179
Song, B.-J., Abdelmegeed, M. A., Henderson, L. E., Yoo, S.-H., Wan, J., Purohit, V., Hardwick, J. P., & Moon, K.-H. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/781050 · Cited by 67
Self-citationDynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis
Sommars, M. A., Ramachandran, K., Senagolage, M. D., Futtner, C. R., Germain, D. M., Allred, A. L., Omura, Y., Bederman, I. R., & Barish, G. D. (2019) · eLife · doi:10.7554/elife.43922 · Cited by 66
“PPARa is critical for the fasting induction of genes mediating peroxisomal and mitochondrial fatty acid b-oxidation as well as microsomal w-hydroxylation (Contreras et al., 2013; Gao et al., 2015; Hardwick et al., 2009; Hashimoto et al., 2000; Kersten et al., 1999; Leone et al., 1999; Montagner et al., 2016).”
Background
Metadata
- Authors
- Hardwick, J. P., Osei-Hyiaman, D., Wiland, H., Abdelmegeed, M. A., & Song, B.-J.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 2009
- Issue
- 1
- Pages
- 952734-952734
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W1964775061
- Cited by
- 148
- References
- 27
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω‐Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. https://app.cochat.ai/papers/10.1155/2009/952734
- The paper
- Hardwick, J. P., Osei-Hyiaman, D., Wiland, H., Abdelmegeed, M. A., & Song, B.-J. (2009). PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω‐Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Research. https://doi.org/10.1155/2009/952734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.